Apotent erythropoietin-mimicking human antibody interacts through a novel binding site

Blood

Volumn 110, Issue 7, 2007, Pages 2408-2413

  Liu, Zhihong ^a   Stoll, Vincent S ^a   DeVries, Peter J ^a   Jakob, Clarissa G ^a   Xie, Nancy ^a   Simmer, Robert L ^a   Lacy, Susan E ^a   Egan, David A ^a   Harlan, John E ^a   Lesniewski, Richard R ^a   Reilly, Edward B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 007; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; GLYCOSYLATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSGENIC MOUSE; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; ERYTHROPOIESIS; GENETICS; HEMATOCRIT; IMMUNOLOGY; METABOLISM; MOLECULAR MIMICRY; MOUSE MUTANT; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; STRUCTURAL HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATOCRIT; HUMANS; MICE; MICE, KNOCKOUT; MODELS, MOLECULAR; MOLECULAR MIMICRY; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ERYTHROPOIETIN; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 34948831582     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-04-083998     Document Type: Article

References (34)

1. Graber SE, Krantz SB. Erythropoietin and the control of red blood cell production. Annu Rev Med. 1978;29:51-66.
2. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001;84:3-10.
3. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-440.
4. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363:1768-1771.
5. Schneider H, Chaovapong W, Matthews DJ, et al. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood. 1997;89:473-482.
6. Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliott G. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem. 1996;271:24691-24697.
7. Syed RS, Reid SW, Li C, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395:511-516.
8. Chiba S, Takaku F, Tange T, et al. Establishment and erythroid differentiation of a cytokine-dependent human leukemic cell line F-36: a parental line requiring granulocyte-macrophage colony-stimulating factor or interleukin-3, and a subline requiring erythropoietin. Blood. 1991;78:2261-2268.
9. Johnson DL, Middleton SA, McMahon F, et al. Refolding, purification, and characterization of human erythropoietin binding protein produced in Escherichia coli. Protein Expr Purif. 1996;7:104-113.
10. Kumar A, Arora R, Kaur P, Chauhan VSSharma P. "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surfaceantigen peptide. J Immunol. 1992;148:1499-1505.
11. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci U S A. 1996;93:7843-7848.
12. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15:553-557.
13. Harlow E, Lane D. Reagents. In: Antibodies, A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988:613-633.
14. Otwinowski Z, Minor W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307-326.
15. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005;61:458-464.
16. Vagin A, Teplyakov A. MOLREP: an automated program for molecular replacement. J Appl Crystallogr. 1997;30:1022-1025.
17. Faelber K, Kirchhofer D, Presta L, Kelley RF, Muller YA. The 1.85 A resolution crystal structures of tissue factor in complex with humanized Fab D3h44 and of free humanized Fab D3h44: revisiting the solvation of antigen combining sites. J Mol Biol. 2001;313:83-97.
18. Livnah O, Johnson DL, Stura EA, et al. An antagonist peptide-EPOR receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol. 1998;11:993-1004.
19. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-990.
20. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1998;54:905-998.
21. Badger J, Berard D, Kumar RA, et al. CNX Software Manual. San Diego, CA: Molecular Simulations; 1999.
22. Murshudov GN, Vagin AA, Lebedev A, Wilson KS, Dodson EJ. Efficient anisotropic refinement of Macromolecular structures using FFT. Acta Crystallogr D Biol Crystallogr. 1999;55:247-255.
23. Komatsu N, Yamamoto M, Fujita H, et al. Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood. 1993;82:456-464.
24. Yu X, Lin CS, Costantini F, Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood. 2001;98:475-477.
25. Liu ZY, Chin K, Noguchi CT. Tissue specific expression of human erythropoietin receptor in transgenic mice. Dev Biol. 1994;166:159-169.
26. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002;87:268-276.
27. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283:990-993.
28. Philo JS, Aoki KH, Arakawa T, Nahri LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry. 1996;35:1681-1691.
29. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-2395.
30. Naranda T, Wong K, Kaufman RI, Goldstein A, Olsson L. Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site. Proc Natl Acad Sci U SA. 1999;96:7569-7574.
31. Tong EM, Nissenson AR. Erythropoietin and anemia. Semin Nephrol. 2001;21:190-203.
32. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205-1210.
33. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290-299.
34. Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004;93:177-185.